Skip to main content
letter
. 2016 Nov;101(11):e445–e448. doi: 10.3324/haematol.2016.142521

Figure 1.

Figure 1.

BNIP3 and BNIP3L expression and methylation status in bone marrow cells from MDS and AML patients. BNIP3 (A), BNIP3L (B) and HIF-1α (C) mRNA expression in total bone marrow cells from healthy donors, and from patients with diagnosis of myelodysplastic syndromes (MDS) stratified by ‘WHO (World Health Organization) 2008 classification and acute myeloid leukemia (AML). The “y” axis represents the relative BNIP3, BNIP3L or HIF-1α mRNA expression normalized to HPRT endogenous control; sample from a healthy donor was used as the calibration sample. Each dot represents one subject and horizontal lines indicate medians. The numbers of subjects studied and the P values (Mann–Whitney test) are indicated. (D) Correlation between BNIP3 or BNIP3L and HIF-1α expression in primary bone marrow cells from MDS and AML patients. Spearman correlation test; N, P and r values are indicated in the graph. (E) BNIP3L mRNA levels in total bone marrow cells from five MDS patients at diagnosis and after disease progression. The “y” axis represents the fold change of BNIP3L mRNA expression normalized to HPRT endogenous control at diagnosis (calibration sample) and after disease progression; WHO 2008 classification and bone marrow blast percentage are indicated. Data are presented in arbitrary units (a.u.). (F) Overall survival of MDS patients categorized as median of BNIP3L expression levels (Kaplan-Meier curves). Patients were subgrouped by higher BNIP3L expression (above median; 1.73) and lower BNIP3L expression (below median). P value is indicated. (G) BNIP3 and BNIP3L methylation in bone marrow samples from healthy donors and from MDS and AML patients. Percentage of positive methylation and total number of samples are indicated. RA: refractory anemia; RARS: refractory anemia with ringed sideroblasts; del(5q): MDS with isolated del(5q); RCMD: refractory cytopenia with multilineage dysplasia; RAEB-1: refractory anemia with excess blasts-1; RAEB-2: refractory anemia with excess blasts-2; MDS: myelodysplastic syndromes; MRC; myelodysplastic-related changes.